ClinicalTrials.gg
RecruitingNCT05459935Updated Sep 15, 2026

Photobiomodulation for Pediatric Hypertrophic Tonsils

An interventional study of PBM Tonsil Arm and Sham PBM Tonsil Arm in Pediatric Sleep Apnea, Obstructive Sleep Apnea and Tonsils Hypertrophy, sponsored by University of Alberta. Recruiting at 1 site in Canada. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by University of Alberta · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Sleep Apnea, Obstructive by University of Alberta — 5 open to participants now, 5 under way, none of them phase 3. Sleep Apnea, Obstructive · University of Alberta.

Started
2022
with 2 others
No phase
2 of 10
1 open now
Registered
4th of 10
by date

Among the 10 studies in Sleep Apnea, Obstructive by University of Alberta, this one is one of 3 that started in 2022, is one of 2 with no phase, and was the 4th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

5 of the 10 studies in Sleep Apnea, Obstructive by University of Alberta are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Sleep Apnea, Obstructive by University of Alberta, or all of them as a file.
02

Study summary

Pediatric obstructive sleep apnea is a medical condition where a child has great difficulty with breathing, or stops breathing all together, while asleep. This is a medical condition for which the primary treatment is usually a surgery targeted towards removing swollen tonsils and adenoids. However, surgical removal of tonsils and adenoids comes with its own risks of complications during and after surgery including secondary hemorrhage and long term increased risks for respiratory and infectious diseases. Perhaps more importantly, surgical removal of swollen tonsils and adenoids does not guarantee successful treatment of a child's obstructive sleep apnea.

The use of laser light therapy in a non-cutting manner (known as photobiomodulation and abbreviated as PBM) has been a relatively new development within medicine. Recently, dentists have begun to use PBM as a method to treat adult snoring and, with lesser success, adult obstructive sleep apnea. To date, there are no known side effects to the use of PBM for the treatment of any sleep breathing disorders. However, no research has been published on the use of PBM for the treatment of pediatric obstructive sleep apnea or swollen tonsils in children

The purpose of this project is to determine whether photobiomodulation can provide a beneficial effect on pediatric hypertrophic tonsils and pediatric obstructive sleep apnea and, if it does, to create the appropriate workflow, referral pathways, and treatment parameters for clinicians to provide this treatment as a multidisciplinary approach in a clinical setting.

The investigators hypothesize that photobiomodulation can be used successfully to decrease the pediatric hypertrophic tonsils in children with symptoms of an pediatric obstructive sleep apnea and will also result in improved AHI scores (be able to breath significantly better when sleeping) in these children.

03

Conditions studied

  • Pediatric Sleep Apnea
  • Obstructive Sleep Apnea
  • Tonsils Hypertrophy
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Brodsky visually graded tonsils 3/4
  • patient must assent, parent must consent, to all pre and post follow up including sleep testing
  • patient and parent must agree to normal referral protocols regardless of participation within this study or not

Exclusion criteria

Exclusion Criteria:

  • visual indication of cancerous growth
  • currently under treatment (pharmacologic, other) for hypertrophic tonsils
  • already scheduled for surgical intervention of hypertrophic tonsils
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    PBM Tonsil Arm

    Photobiomodulation exposure of hypertrophic tonsils

    Device: PBM Tonsil Arm

  • Sham comparator
    Tonsil Control Arm

    Sham (non-powered) exposure of hypertrophic tonsils

    Device: Sham PBM Tonsil Arm

Interventions

  • DevicePBM Tonsil Arm

    exposure of hypertrophic tonsils to photobiomodulation

    Also known as: Fotona Lightwalker AT S

  • DeviceSham PBM Tonsil Arm

    non-powered exposure of hypertrophic tonsils to photobiomodulation

    Also known as: Fotona Lightwalker AT S - non-powered

06

What researchers measure

Primary outcomes

  1. Tonsil Size

    Tonsil size grading (Brodsky score): 0-4, 0 being not present 4 being restrictive to entire airway. Lower scores are better. Each integer represents 25% obstruction of airway (0 being not visible, 1 being 0-25%, 2 being 25-50%, 3 being 50-75%, 4 being 75-100%). There is no abbreviated scale title.

    Time frame: immediately after intervention

Secondary outcomes

  1. AHI Score

    Comparisons of before and after AHI score by portable sleep testing device

    Time frame: Next Day (next night)

  2. Questionnaire Improvement

    Comparisons of before and after PSQ (pediatric sleep questionnaire) scores

    Time frame: night after, per quarter after for 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Jul 2030, 92 months after the start.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 92 months is above that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2022
First posted
Jul 15, 2022
StartActual
Oct 15, 2022
Primary completionEst.
Jul 6, 2030
CompletionEst.
Dec 6, 2030
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05459935
Responsible party
Sponsor
First posted
Jul 15, 2022
Start date
Oct 15, 2022
Primary completion
Jul 6, 2030 (estimated)
Completion
Dec 6, 2030 (estimated)
Last update
Sep 15, 2026

Study contacts

Manuel Lagravere, DDS, PhD
Contact
manuel@ualberta.ca
(780) 492-7696

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion